Gene therapy for bladder control: 5-year safety watch begins
Knowledge-focused
Not yet recruiting
This study follows 16 people who already received EG110A, a gene therapy for overactive bladder caused by spinal cord injury. Researchers will track side effects and how well the treatment works over five years. The goal is to understand long-term safety and dosing.
Phase: PHASE1, PHASE2 • Sponsor: EG 427 • Aim: Knowledge-focused
Last updated May 11, 2026 20:52 UTC